Beta Bionics, Inc. (BBNX) Stock Analysis
A live, multi-source view of Beta Bionics, Inc. (BBNX): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Beta Bionics, Inc.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
Sector: Healthcare · Industry: Medical Devices · United States · 420 employees · betabionics.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Beta Bionics, Inc. (BBNX) had a market capitalization of $873.7M (forward -8.4); the shares traded in a 52-week range of $8.80 – $32.71 (-1.4% over the year).
- Market cap
- $873.7M
- Enterprise value
- $699.7M
- Forward P/E
- -8.4
- Price / book
- 3.41
- EPS (trailing)
- $-1.56
- EPS (forward)
- $-2.31
- Payout ratio
- 0.0%
- 52-week range
- $8.80 – $32.71
- 52-week change
- -1.4%
- Average volume
- 1.2M
- Shares outstanding
- 45.0M
- Short % of float
- 16.74%
- Profit margin
- -61.3%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Beta Bionics, Inc. (BBNX) last closed at $16.59 (the last completed close before that scan).
Technicals at the scan: RSI 40 (neutral territory), price -12.6% versus its 20-day average, 20-day versus 50-day average spread +10.1%, MACD histogram -0.38.
Sentiment inputs: StockTwits 89% bullish; analyst consensus score 69/100.
Next scheduled company event: in 46 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of BBNX; corporate insiders filed 0 buys and 1 sell (1 filer, latest disclosure 2026-09-10). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Mark Hopman (0B/1S). Who is trading what
RapidTradeView pick record
BBNX has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Beta Bionics, Inc. (BBNX) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell BBNX.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.